Phase II study of dasatinib (BMS-354825) for advanced 'triple-negative' breast cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2012
At a glance
- Drugs Dasatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2008 Checked against the ClinicalTrials.gov record.
- 28 Sep 2008 Actual number of patients enrolled was 44 according to the ClinicalTrials.gov record.